Lexeo Therapeutics, Inc. (LXEO) - Market Cap to Earnings

Symbol and logo of brand Lexeo Therapeutics, Inc. (LXEO)

Lexeo Therapeutics (LXEO) operations are protected by the humanitarian status of medicine and US regulations, which mitigates external risks. The company maintains liquidity through moderate R&D expenditures and reliable capital until it reaches break-even. The price indicator on the GURU.Markets chart, with a value of -2.70, complements data regarding partnerships with clinics treating heart and brain pathologies.

LXEO lexeotx.com: Price to Earnings Ratio in the range 03/12/2024 - 11/12/2026

Comprehensive metric breakdowns and analytics for Lexeo Therapeutics Inc. (LXEO)

- current price and projected stock value:
Share Price Lexeo|LXEO - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Lexeo Therapeutics, Inc.|LXEO - Total Company Value
- book value of equity indicators:
Net Asset Value per Share Lexeo Therapeutics|LXEO - Company Net Assets|Market Value to Book Value lexeotx.com|LXEO - Cumulative Company Assets
- company liabilities and liquidity data:
Aggregate Debt to Capital Lexeo Therapeutics|LXEO - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Lexeo|LXEO - Company Aggregate Debts|Debts to Book Value Lexeo Therapeutics, Inc.|LXEO - Company Long-Term Debt|Company Short-Term Loans and Borrowings Lexeo Therapeutics|Quick Ratio lexeotx.com
- business earnings and investment ratios data:
LXEO - Company Net Income|Forward Earnings Lexeo Therapeutics|LXEO - P/E Multiple|Projected Price to Earnings Ratio Lexeo|LXEO - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Lexeo Therapeutics, Inc.|LXEO - Operating profit before deduction of amortization|Earnings per share for the last four quarters Lexeo Therapeutics|LXEO - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months lexeotx.com|LXEO - Earnings growth in current year|Expected earnings per share growth for next year Lexeo Therapeutics
Summary company analysis:LXEO (lexeotx.com)
Finished products of Lexeo Therapeutics

A defensive portfolio is constructed by filtering for assets with a sustainable price-to-earnings ratio. The P/E ratio is calculated as the ratio of market capitalization to annual net income, measuring the investment payback period. For Lexeo Therapeutics (LXEO), this metric reflects the market valuation of the efficiency of implementing robotic bioreactors into gene therapy production. Analyzing the P/E level of Lexeo Therapeutics (LXEO) allows for the determination of whether the asset is overbought relative to the pace of its capacity automation.

Analysis of competing companies

Price to Earnings Multiple TEM (Tempus AI Inc)|P/E Multiple QGEN|IONS - Market Cap to Earnings|Price to Earnings Ratio Repligen Corp. RGEN|Avidity Corp (RNA) - Market Cap to Earnings|CRSP: Price to Earnings Ratio|Company Value to Net Income WGS (genedx.com)|RARE (Ultragenyx) - Price to Earnings Ratio|BEAM: Market Price to Net Income Ratio|SRPT (Sarepta Therapeutics Inc) - P/E Multiple|TWST: Company Value to Net Income|P/E Multiple TXG|NTLA - Market Cap to Earnings|Price to Earnings Ratio Stoke Therapeutics, Inc. STOK|Company Value to Net Income BLFS|Wave Life Sciences Corp - P/E Multiple|MAZE - P/E Multiple|Sionna Therapeutics Inc (SION) - Price to Earnings Ratio|Market Cap to Net Income PRME (primemedicine.com)|TSHA (Taysha Gene Therapies, Inc.) - P/E Multiple|Market Cap to Earnings uniQure NV QURE|Price to Earnings Ratio MGTX (MeiraGTx PLC)|P/E Multiple REGENXBIO Corp (RGNX)|Solid Biosciences Inc. - Price to Earnings Ratio|Market Price to Net Income Ratio OCGN (ocugen.com)|PacBio - P/E Multiple|Business Payback Period Benitec Biopharma Inc BNTC|DSGN: P/E Multiple|Price to Earnings Ratio Rocket Corp|Price to Earnings Ratio 4D Molecular Therapeutics|Korro Bio, Inc (KRRO) - Business Payback Period|Price to Earnings Ratio Editas Medicine (EDIT)|Price to Earnings Ratio SLN (Silence Therapeutics PLC)|ProQR Therapeutics - Price to Earnings Ratio|CDXS: Price to Earnings Multiple|Sangamo Therapeutics - P/E Multiple|Market Cap to Earnings Nautilus Biotechnology|Metagenomi (MGX) - Price to Earnings Ratio|Market Cap to Earnings precisionbiosciences.com (DTIL)|GBIO (Generation Bio Co) - P/E Multiple|Price to Earnings Multiple BOLD (Boundless Bio Inc)|Price to Earnings Ratio Exicure, Inc. (XCUR)|imunon.com - Price to Earnings Multiple|P/E Multiple PHIO (Phio Pharmaceuticals Corp.)|P/E Multiple Mustang Bio Inc MBIO|RNAZ - Price to Earnings Ratio|BNGO: Price to Earnings Ratio|APDN: P/E Multiple|Market Cap to Earnings bluebirdbio.com (BLUE)|Price to Earnings Ratio IPA|Price to Earnings Multiple OMGA (Omega Therapeutics Inc)|P/E Multiple OMIC|RGLS - Market Cap to Earnings|Price to Earnings Ratio Syros Pharmaceuticals SYRS|telesisbio.com (TBIO) - Market Cap to Earnings|TCON: Price to Earnings Ratio|Company Value to Net Income UBX (Unity Biotechnology Inc.)